诺华针对一种罕见肌肉萎缩症的实验性药物del-desiran原本有望成为赢家，这家瑞士公司的首席执行官预测其年峰值销售额将达到50亿美元。
Novartis’ experimental del-desiran for a rare type of muscular dystrophy was expected to be a winner, with the Swiss company's CEO predicting annual peak sales of $5 billion.
当上月一项后期试验未能达到目标时，股价下跌了11%，市值蒸发了300亿美元。
When a late-stage trial missed its goal last month, shares fell 11%, erasing $30 billion in market value.